Mesoblast (MESO) announced its addition to the S&P Dow Jones Indices’ S&P/ASX 200 Index effective March 6, 2025 on the Australian Stock Exchange.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO:
- Mesoblast’s Earnings Call: RYONCIL Approval & Growth
- Buy Rating for Mesoblast Driven by Promising Market Position and Strong Financial Backing
- Mesoblast Reports FDA Approval and Financial Results
- Mesoblast Appoints Dr. Gregory George to Board, Enhancing Strategic and Operational Expertise
- Mesoblast price target raised to $24 from $15 at Piper Sandler
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue